Cefotetan
From Wikipedia, the free encyclopedia
Cefotetan
|
|
Systematic (IUPAC) name | |
(7S)-7-{[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene) 1,3-dithietane-2-carbonyl]amino}-7-methoxy- 3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo- 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
|
Identifiers | |
CAS number | |
ATC code | J01 |
PubChem | |
Chemical data | |
Formula | C17H17N7O8S4 |
Mol. mass | 575.623 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Cefotetan is an injectable antibiotic of the cephamycin type for prophylaxis and treatment of bacterial infections. It is often grouped together with second-generation cephalosporins and has a similar antibacterial spectrum, but with additional anti-anaerobe converage.
Cefotetan was developed by Yamanouchi. It is marketed outside Japan by AstraZeneca with the brand names Apatef and Cefotan.
[edit] External links
- Cefotan official web site run by AstraZeneca US
- Cefotetan entry in RxList
|